UNICREDIT BANK/CALL/EVOTEC/20/1/19.03.25 Share Price

Warrant

DE000HD3ZZ01

Market Closed - BOERSE MUENCHEN 20:45:10 31/05/2024 BST
0.08 EUR +29.03% Intraday chart for UNICREDIT BANK/CALL/EVOTEC/20/1/19.03.25
1 month-61.90%
Date Price Change
31/05/24 0.08 +29.03%
30/05/24 0.062 -13.89%
29/05/24 0.072 -7.69%
28/05/24 0.078 -17.02%
27/05/24 0.094 +44.62%

Real-time BOERSE MUENCHEN

Last update May 31, 2024 at 08:45 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer UniCredit UniCredit
WKN HD3ZZ0
ISINDE000HD3ZZ01
Date issued 21/03/2024
Strike 20
Maturity 19/03/2025 (291 Days)
Parity 1 : 1
Emission price 1.32
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.31
Lowest since issue 0.039

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.655 EUR
Average target price
20.79 EUR
Spread / Average Target
+140.21%
Consensus